Clinical trials: Liver Cancer, completed
Liver Tumor, Liver Neoplasms
PET/CT-Assessment of Liver Tumor Ablation
In this research study, the investigators are evaluating whether ammonia PET scans or FDG PET perfusion scans are more useful in helping radiologists determine whether liver tumors were successfully destroyed by the heating or…
- Trial name
- NCT02018107
- Testing
- N-13 ammonia or F-18 fluorodeoxyglucose, PET scan
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Dana-Farber Cancer Institute
Adult Hepatocellular Carcinoma, Localized Resectable Adult Liver Carcinoma
PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
This clinical trial studies positron emission tomography (PET)/computed tomography (CT) in diagnosing patients with liver cancer undergoing surgical resection.
- Trial name
- NCT01395030
- Testing
- Computed Tomography, 18F-fluoromethylcholine, Positron Emission Tomography
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Queen's Medical Center
Liver Cancer
Liver Cancer Community Education
This study proposes to bridge the gap between evidence and action and combat rising liver cancer rates attributed to Hepatitis B and C infection in Philadelphia by identifying neighborhoods with higher than expected rates of…
- Trial name
- NCT04272619
- Testing
- LIVE-R Life Education
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Hemorrhage
PeproStat Haemostat Study in Subjects Undergoing Liver Surgery
The purpose of this First in Man study is to evaluate the safety and tolerability, as well as to explore efficacy of PeproStat, a new peptide based coagulant (haemostat), when used in patients undergoing open liver resection…
- Trial name
- NCT02204930
- Testing
- PeproStat
- Where
- 4 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Haemostatix Ltd
HCC, Metastasis
Monopolar Radiofrequency Ablation Using a Dual Switching System and a Separable Clustered Electrode (Octopus®)
Increasing ablative zone is an essential part to improve technical success and long term outcome in patient treated with radiofrequency ablation (RFA).
- Trial name
- NCT02675881
- Testing
- DSM, separable clustered electrode
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Adult Liver Carcinoma, Liver Cirrhosis
[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer
This clinical trial studies how well 18F-fluoromisonidazole ([18F]FMISO) positron emission tomography (PET)/computed tomography (CT) works after transcatheter arterial embolization in imaging tumors in patients with liver cancer.
- Trial name
- NCT02695628
- Testing
- 18F-Fluoromisonidazole, Arterial Embolization, Computed Tomography
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Stanford University
Hepatitis B
Activation of Hepatitis B Virus (HBV) in Hepatitis B Surface Antigen (HBsAg) - Negative But Hepatitis B Core Antibody (Anti-HBc) - Positive Patients
Individuals with resolved hepatitis B, characterized as hepatitis B surface antigen (HBsAg)-negative and hepatitis B core antibody-positive, have latent hepatitis B virus (HBV) infection in their liver tissue.
- Trial name
- NCT00881036
- Where
- Japan
- Volunteers
- 33 people
- Sponsor
- Kyoto University
Hepatocellular Carcinoma, Anti-PD1 Antibody
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
For the advanced hepatocellular carcinoma (HCC), the targeted therapy and immunotherapy are recommended. This study focused on the management of Lenvatinib combined anti-PD1 antibody for the HCC.
- Conditions
- Hepatocellular Carcinoma, Anti-PD1 Antibody, Liver Diseases
- Trial name
- NCT04627012
- Testing
- Lenvatinib, Opdivo, Camrelizumab
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Sun Yat-sen University
Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
This early phase IIA trial studies how well celecoxib, recombinant interferon alfa-2b, and rintatolimod work in treating patients with colorectal cancer that as spread to the liver.
- Conditions
- Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7
- Trial name
- NCT03403634
- Testing
- Celecoxib, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Roswell Park Cancer Institute
Advanced Solid Tumors
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of budigalimab.
- Trial name
- NCT03000257
- Testing
- Venetoclax, Rovalpituzumab Tesirine, ABBV-181
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 182 people
- Sponsor
- AbbVie
Pancreatic Cancer
Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer with Homologous Recombination Deficiency That Has Spread to the Liver
The researchers are doing this study to test the combination of radiation therapy (RT) and low dose chemotherapy in people with metastatic pancreatic cancer that has a homologous recombination deficiency (HRD) and has spread to…
- Trial name
- NCT05182112
- Testing
- Whole liver irradiation (WLI), Gemcitabine and Cisplatin
- Where
- 7 sites in United States
- Volunteers
- 1 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma
The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study
Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, any treatment guidelines do not specify the criteria for repeating TACE.
- Trial name
- NCT05121571
- Testing
- HAIC, Sorafenib
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Sun Yat-sen University
Urothelial Carcinoma, Non-Small Cell Lung Cancer
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This is a non-interventional, multi-country, multi-centre, multiple cohort prospective study, with retrospective collection of prior medical/treatment history data from medical records, designed to assess the real-world outcomes…
- Conditions
- Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- IMreal (NCT03782207)
- Testing
- Atezolizumab
- Where
- 257 sites in Argentina, Austria and 28 more
- Volunteers
- 2,756 people
- Sponsor
- Hoffmann-La Roche
Non-hematologic Malignancies, Metastatic Melanoma
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Temozolomide (chemotherapy) in treating patients with solid tumors, including metastatic melanoma (MM), BRCA deficient…
- Conditions
- Non-hematologic Malignancies, Metastatic Melanoma, Breast Cancer, Ovarian Cancer
- Trial name
- NCT00526617
- Testing
- ABT-888, Temozolomide
- Volunteers
- 41 people
- Sponsor
- AbbVie
Cancer, COPD
SELF-BREATHE RCT for Chronic Breathlessness
A feasibility RCT comprising two groups: 1. Intervention (SELF-BREATHE in addition to standard NHS care) 2. Control group (standard / currently available NHS care)
- Conditions
- Cancer, COPD, Asthma, Bronchiectasis Adult
- Trial name
- NCT04574050
- Testing
- SELF-BREATHE
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- King's College Hospital NHS Trust
Liver Cancer
Evaluation of the Signa Excite 3.0 T MRI Excite for Detection and Characterization of Liver Lesions
Primary Objective: 1. To compare the efficacy of 1.5T vs. 3T T1 and T2-weighted MR images sequences for the detection and evaluation of liver lesions.
- Trial name
- NCT00527891
- Testing
- Signa Excite 3.0 T MRI Scan
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Cirrhosis, Hepatocellular Carcinoma
Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
This phase II trial studies how well simvastatin works in preventing liver cancer in patients with liver cirrhosis. Simvastatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT02968810
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma, Desflurane Adverse Reaction
Effect of Propofol and Desflurane on Nucleic Acid of Liver Circulating Tumor
To investigate the effects of perioperative anesthetic drugs propofol and desflurane on circulating tumor nucleic acids (CK7, ELF3, EGFR and EphB4 mRNA) in the blood of patients with liver cancer, so as to provide scientific…
- Conditions
- Hepatocellular Carcinoma, Desflurane Adverse Reaction, Propofol Adverse Reaction, Circulating Tumor Cells
- Trial name
- NCT05502458
- Testing
- Desflurane, Propofol
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome…
- Conditions
- Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT03829436
- Testing
- Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Tempest Therapeutics
Hepatocellular Carcinoma, Radioembolization
Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most-common cancer worldwide and the second most-common cause of cancer mortality. Liver resection is the first-line curative treatment for huge HCC.
- Trial name
- NCT02724436
- Testing
- TACE, radioembolization with Y-90
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital